MaaT Pharma SA (EPA:MAAT)
France · Delayed Price · Currency is EUR 1.082
+0.012 (1.12%)
Nov 12, 2026, 9:16 AM CET
MaaT Pharma Stock Forecast
EPA-MAAT's stock price has decreased by -71.69% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
According to 2 analysts polled by S&P Global, MaaT Pharma stock has a consensus rating of "Buy" and an average price target of €6.50. The average 1-year stock price forecast is 500.74% higher than the current stock price, while the lowest is €3.00 (+177.26%) and the highest is €10.00 (+824.21%).
Price Target: €6.50 (+500.74%)
Analyst Consensus: Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for MaaT Pharma stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Sep '26 | Oct '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 1 | 2 | 1 | 1 |
| Buy | 1 | 1 | 1 | 0 | 0 | 0 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 3 | 3 | 2 | 2 |
Financial Forecast
Revenue This Year
5.78M
from 4.52M
Increased by 27.71%
Revenue Next Year
20.33M
from 5.78M
Increased by 251.86%
EPS This Year
-2.12
from -1.95
EPS Next Year
-0.97
from -2.12
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is EUR.